Cargando…

Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study

The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Teg...

Descripción completa

Detalles Bibliográficos
Autores principales: Hachulla, Eric, Le Masson, Gwendal, Solé, Guilhem, Hamidou, Mohamed, Desnuelle, Claude, Azulay, Jean-Philippe, Besson, Gérard, Swiader, Laure, Abad, Sébastien, Antoine, Jean-Christophe, Bouhour, Françoise, Créange, Alain, Grenouillet, Marike, Magy, Laurent, Marcel, Sébastien, Paquet, Jean-Michel, Rouhart, François, Ziegler, François, Mathis, Stéphane, Gauthier-Darnis, Marc, Puget, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875056/
https://www.ncbi.nlm.nih.gov/pubmed/29736397
http://dx.doi.org/10.1155/2018/8147251
_version_ 1783310292313178112
author Hachulla, Eric
Le Masson, Gwendal
Solé, Guilhem
Hamidou, Mohamed
Desnuelle, Claude
Azulay, Jean-Philippe
Besson, Gérard
Swiader, Laure
Abad, Sébastien
Antoine, Jean-Christophe
Bouhour, Françoise
Créange, Alain
Grenouillet, Marike
Magy, Laurent
Marcel, Sébastien
Paquet, Jean-Michel
Rouhart, François
Ziegler, François
Mathis, Stéphane
Gauthier-Darnis, Marc
Puget, Sophie
author_facet Hachulla, Eric
Le Masson, Gwendal
Solé, Guilhem
Hamidou, Mohamed
Desnuelle, Claude
Azulay, Jean-Philippe
Besson, Gérard
Swiader, Laure
Abad, Sébastien
Antoine, Jean-Christophe
Bouhour, Françoise
Créange, Alain
Grenouillet, Marike
Magy, Laurent
Marcel, Sébastien
Paquet, Jean-Michel
Rouhart, François
Ziegler, François
Mathis, Stéphane
Gauthier-Darnis, Marc
Puget, Sophie
author_sort Hachulla, Eric
collection PubMed
description The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Tegeline, an IVIg from LFB Biomedicaments, and assess its safety at home, compared to in hospital, in patients with AID. The included patients were at least 18 years old, suffering from AID, and treated with at least 1 cycle of Tegeline at home after receiving 3 consecutive cycles of hospital-based treatment with Tegeline at a dose between 1 and 2 g/kg/cycle. Forty-six patients with AID, in most cases immune-mediated neuropathies, received a total of 138 cycles of Tegeline in hospital and then 323 at home. Forty-five drug-related adverse events occurred in 17 patients who received their cycles at home compared to 24 adverse events in hospital in 15 patients. Serious adverse events occurred in 3 patients during home treatment, but they were not life-threatening and did not lead to discontinuation of Tegeline. Forty-five patients continued their treatment with Tegeline at home or in hospital; 39 (84.8%) were still receiving home treatment at the end of the study. In conclusion, the study demonstrates the good safety profile of Tegeline administered at home at high doses in patients with AID who are eligible for home administration of Tegeline.
format Online
Article
Text
id pubmed-5875056
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-58750562018-05-07 Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study Hachulla, Eric Le Masson, Gwendal Solé, Guilhem Hamidou, Mohamed Desnuelle, Claude Azulay, Jean-Philippe Besson, Gérard Swiader, Laure Abad, Sébastien Antoine, Jean-Christophe Bouhour, Françoise Créange, Alain Grenouillet, Marike Magy, Laurent Marcel, Sébastien Paquet, Jean-Michel Rouhart, François Ziegler, François Mathis, Stéphane Gauthier-Darnis, Marc Puget, Sophie Biomed Res Int Research Article The efficacy of intravenous immunoglobulins (IVIg) in patients with autoimmune diseases (AID) has been known for several decades. Majority of these patients received IVIg in hospital. A retrospective study was conducted in 22 centers in France to evaluate the feasibility of the administration of Tegeline, an IVIg from LFB Biomedicaments, and assess its safety at home, compared to in hospital, in patients with AID. The included patients were at least 18 years old, suffering from AID, and treated with at least 1 cycle of Tegeline at home after receiving 3 consecutive cycles of hospital-based treatment with Tegeline at a dose between 1 and 2 g/kg/cycle. Forty-six patients with AID, in most cases immune-mediated neuropathies, received a total of 138 cycles of Tegeline in hospital and then 323 at home. Forty-five drug-related adverse events occurred in 17 patients who received their cycles at home compared to 24 adverse events in hospital in 15 patients. Serious adverse events occurred in 3 patients during home treatment, but they were not life-threatening and did not lead to discontinuation of Tegeline. Forty-five patients continued their treatment with Tegeline at home or in hospital; 39 (84.8%) were still receiving home treatment at the end of the study. In conclusion, the study demonstrates the good safety profile of Tegeline administered at home at high doses in patients with AID who are eligible for home administration of Tegeline. Hindawi 2018-03-15 /pmc/articles/PMC5875056/ /pubmed/29736397 http://dx.doi.org/10.1155/2018/8147251 Text en Copyright © 2018 Eric Hachulla et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Hachulla, Eric
Le Masson, Gwendal
Solé, Guilhem
Hamidou, Mohamed
Desnuelle, Claude
Azulay, Jean-Philippe
Besson, Gérard
Swiader, Laure
Abad, Sébastien
Antoine, Jean-Christophe
Bouhour, Françoise
Créange, Alain
Grenouillet, Marike
Magy, Laurent
Marcel, Sébastien
Paquet, Jean-Michel
Rouhart, François
Ziegler, François
Mathis, Stéphane
Gauthier-Darnis, Marc
Puget, Sophie
Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
title Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
title_full Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
title_fullStr Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
title_full_unstemmed Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
title_short Safety of Intravenous Immunoglobulin (Tegeline®), Administered at Home in Patients with Autoimmune Disease: Results of a French Study
title_sort safety of intravenous immunoglobulin (tegeline®), administered at home in patients with autoimmune disease: results of a french study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875056/
https://www.ncbi.nlm.nih.gov/pubmed/29736397
http://dx.doi.org/10.1155/2018/8147251
work_keys_str_mv AT hachullaeric safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT lemassongwendal safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT soleguilhem safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT hamidoumohamed safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT desnuelleclaude safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT azulayjeanphilippe safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT bessongerard safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT swiaderlaure safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT abadsebastien safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT antoinejeanchristophe safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT bouhourfrancoise safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT creangealain safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT grenouilletmarike safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT magylaurent safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT marcelsebastien safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT paquetjeanmichel safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT rouhartfrancois safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT zieglerfrancois safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT mathisstephane safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT gauthierdarnismarc safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy
AT pugetsophie safetyofintravenousimmunoglobulintegelineadministeredathomeinpatientswithautoimmunediseaseresultsofafrenchstudy